$BIORQ
BIORA THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000095017024127060 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $32.00K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.65M
YoY Change -16.64%
% of Gross Profit
Research & Development $5.610M
YoY Change -46.81%
% of Gross Profit
Depreciation & Amortization $100.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $16.26M
YoY Change -30.28%
Operating Profit -$16.23M
YoY Change -30.42%
Interest Expense $2.016M
YoY Change -22.22%
% of Operating Profit
Other Income/Expense, Net -$12.28M
YoY Change -76.44%
Pretax Income -$22.26M
YoY Change -69.69%
Income Tax -$44.00K
% Of Pretax Income
Net Earnings -$18.40M
YoY Change -74.95%
Net Earnings / Revenue -57506.25%
Basic Earnings Per Share -$5.04
Diluted Earnings Per Share -$5.04
COMMON SHARES
Basic Shares Outstanding 4.523M 36.47M
Diluted Shares Outstanding 3.653M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.196M
YoY Change -74.63%
Cash & Equivalents $3.000M
Short-Term Investments
Other Short-Term Assets $45.00K
YoY Change -73.84%
Inventory
Prepaid Expenses $1.945M
Receivables
Other Receivables
Total Short-Term Assets $6.054M
YoY Change -68.55%
LONG-TERM ASSETS
Property, Plant & Equipment $1.175M
YoY Change -4.94%
Goodwill $6.072M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $193.0K
YoY Change -96.94%
Total Long-Term Assets $8.451M
YoY Change -45.32%
TOTAL ASSETS
Total Short-Term Assets $6.054M
Total Long-Term Assets $8.451M
Total Assets $14.51M
YoY Change -58.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.916M
YoY Change 77.11%
Accrued Expenses $21.31M
YoY Change 1.0%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $4.527M
YoY Change
Long-Term Debt Due $34.07M
YoY Change
Total Short-Term Liabilities $120.6M
YoY Change 73.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $516.0K
YoY Change -85.53%
Total Long-Term Liabilities $516.0K
YoY Change -85.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $120.6M
Total Long-Term Liabilities $516.0K
Total Liabilities $121.1M
YoY Change -21.08%
SHAREHOLDERS EQUITY
Retained Earnings -$967.1M
YoY Change 3.38%
Common Stock $879.5M
YoY Change 5.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$106.6M
YoY Change
Total Liabilities & Shareholders Equity $14.51M
YoY Change -58.2%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$18.40M
YoY Change -74.95%
Depreciation, Depletion And Amortization $100.0K
YoY Change 0.0%
Cash From Operating Activities -$8.730M
YoY Change -20.85%
INVESTING ACTIVITIES
Capital Expenditures $19.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$19.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.620M
YoY Change -332.28%
NET CHANGE
Cash From Operating Activities -8.730M
Cash From Investing Activities -19.00K
Cash From Financing Activities 6.620M
Net Change In Cash -2.129M
YoY Change -84.66%
FREE CASH FLOW
Cash From Operating Activities -$8.730M
Capital Expenditures $19.00K
Free Cash Flow -$8.749M
YoY Change -20.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
337000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
818000
CY2024Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
179000
CY2023Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
2211000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
516000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3029000
CY2024Q3 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q3 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001580063
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://bioratherapeutics.com/20240930#AccruedExpensesAndOtherLiabilitiesCurrent
us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2024-04-01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39334
dei Entity Registrant Name
EntityRegistrantName
Biora Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3950390
dei Entity Address Address Line1
EntityAddressAddressLine1
4330 La Jolla Village Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
727-2841
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BIOR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4522702
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3196000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15211000
CY2024Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
868000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
830000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1990000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
6054000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19071000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1175000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1156000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1011000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1614000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3302000
CY2024Q3 us-gaap Goodwill
Goodwill
6072000
CY2023Q4 us-gaap Goodwill
Goodwill
6072000
CY2024Q3 us-gaap Assets
Assets
14505000
CY2023Q4 us-gaap Assets
Assets
31215000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6916000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2843000
CY2024Q3 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21404000
CY2023Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17319000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
18688000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
40834000
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4527000
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
14344000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2024Q3 bior Related Party Senior Secured Convertible Notes Current
RelatedPartySeniorSecuredConvertibleNotesCurrent
19721000
CY2023Q4 bior Related Party Senior Secured Convertible Notes Current
RelatedPartySeniorSecuredConvertibleNotesCurrent
1976000
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35018000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
120618000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62972000
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
9966000
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14591000
CY2024Q3 bior Related Party Senior Secured Convertible Notes Non Current
RelatedPartySeniorSecuredConvertibleNotesNonCurrent
0
CY2023Q4 bior Related Party Senior Secured Convertible Notes Non Current
RelatedPartySeniorSecuredConvertibleNotesNonCurrent
19179000
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22899000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
516000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3029000
CY2024Q3 us-gaap Liabilities
Liabilities
121134000
CY2023Q4 us-gaap Liabilities
Liabilities
132636000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3778030
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2857484
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3677726
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2783748
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
879530000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
868613000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-967084000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-950958000
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
100304
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
73736
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19078000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19078000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-106629000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-101421000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14505000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31215000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
892000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5610000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10547000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20319000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23720000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10649000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12774000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28102000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30083000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
16259000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
23321000
us-gaap Operating Expenses
OperatingExpenses
48421000
us-gaap Operating Expenses
OperatingExpenses
53803000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16227000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23321000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47529000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53799000
CY2024Q3 us-gaap Interest Expense
InterestExpense
2016000
CY2023Q3 us-gaap Interest Expense
InterestExpense
2592000
us-gaap Interest Expense
InterestExpense
5484000
us-gaap Interest Expense
InterestExpense
7975000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8260000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4568000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-35178000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5271000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12279000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52108000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2170000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52194000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22262000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73453000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20005000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108697000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-44000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-63000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-22218000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-73454000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-19942000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-108702000
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
3816000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
3816000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18402000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-73454000
us-gaap Net Income Loss
NetIncomeLoss
-16126000
us-gaap Net Income Loss
NetIncomeLoss
-108702000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.08
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.08
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-48.89
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-48.89
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.25
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.25
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-85.41
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-85.41
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
1.04
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
1.04
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
1.2
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
1.2
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.04
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-48.89
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-48.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-85.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-85.41
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3652862
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3652862
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1502473
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1502473
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3189308
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3189308
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1272765
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1272765
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-101421000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2824000
CY2024Q1 bior Stock Issued During Period Value Purchase Warrants
StockIssuedDuringPeriodValuePurchaseWarrants
1062000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1539000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4189000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-100185000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2807000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-6000
CY2024Q2 bior Stock Issued During Period Value Purchase Warrants
StockIssuedDuringPeriodValuePurchaseWarrants
24000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1573000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
6465000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89322000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-171000
CY2024Q3 bior Stock Issued During Period Value Purchase Warrants
StockIssuedDuringPeriodValuePurchaseWarrants
-45000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1281000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18402000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-106629000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102287000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12524000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-178000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2384000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17441000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-104998000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-90000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2014000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17807000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-120881000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1691000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
66699000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10531000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-73454000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-118786000
us-gaap Net Income Loss
NetIncomeLoss
-16126000
us-gaap Net Income Loss
NetIncomeLoss
-108702000
bior Gain From Discontinued Operations
GainFromDiscontinuedOperations
3816000
bior Gain From Discontinued Operations
GainFromDiscontinuedOperations
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
326000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
438000
us-gaap Share Based Compensation
ShareBasedCompensation
4393000
us-gaap Share Based Compensation
ShareBasedCompensation
14929000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-10890000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
53198000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3216000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1126000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
100000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-8669000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-35178000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5271000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
38000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1150000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-734000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3389000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8702000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9963000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-427000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1578000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32178000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34754000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
3000000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2806000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6465000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13064000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2819000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10813000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1038000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
471000
bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
1525000
bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
1771000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
177000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1959000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17357000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16863000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12015000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17917000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15211000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3196000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12569000
us-gaap Interest Paid Net
InterestPaidNet
244000
us-gaap Interest Paid Net
InterestPaidNet
1196000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
61000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
bior Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants
ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants
5625000
bior Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants
ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1344000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
50000000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
635000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
59000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
161000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2024Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse split
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3000000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
200000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-967100000
us-gaap Net Income Loss
NetIncomeLoss
-16100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the valuation of stock options, the valuation of goodwill, the valuation of the derivative liabilities associated with the 2028 Convertible Notes, accrual for reimbursement claims and settlements, the valuation of warrant liabilities, assessing future tax exposure and the realization of deferred tax assets, and the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p>
CY2024Q3 bior Restricted Cash Collateral For Credit Cards
RestrictedCashCollateralForCreditCards
200000
CY2023Q4 bior Restricted Cash Collateral For Credit Cards
RestrictedCashCollateralForCreditCards
200000
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
0
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
0
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
0
CY2024Q3 bior Disposal Group Including Discontinued Operation Selling General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense
-3816000
bior Disposal Group Including Discontinued Operation Selling General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense
-3816000
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
-3816000
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
-3816000
CY2024Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
3816000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
3816000
CY2023Q4 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
2800000
CY2023Q4 bior Cost Incurred In Sale Of Property Plant And Equipment
CostIncurredInSaleOfPropertyPlantAndEquipment
200000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1945000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2443000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
45000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
587000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1990000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3580000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3263000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2405000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2107000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1175000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1156000
CY2024Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
300000
CY2023Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
400000
CY2024Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
193000
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
302000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3302000
CY2024Q3 bior Accrual For Reimbursement Claims And Settlements Current
AccrualForReimbursementClaimsAndSettlementsCurrent
3572000
CY2023Q4 bior Accrual For Reimbursement Claims And Settlements Current
AccrualForReimbursementClaimsAndSettlementsCurrent
6337000
CY2024Q3 bior Accrued Legal Fees
AccruedLegalFees
9397000
CY2023Q4 bior Accrued Legal Fees
AccruedLegalFees
1577000
CY2024Q3 bior Commission And Bonus Current
CommissionAndBonusCurrent
3423000
CY2023Q4 bior Commission And Bonus Current
CommissionAndBonusCurrent
2469000
CY2024Q3 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1437000
CY2023Q4 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1367000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
576000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1337000
CY2024Q3 bior Accrued Interest Current
AccruedInterestCurrent
1439000
CY2023Q4 bior Accrued Interest Current
AccruedInterestCurrent
173000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
717000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
896000
CY2024Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
751000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
401000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
542000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
92000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2220000
CY2024Q3 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21404000
CY2023Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17319000
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
14344000
CY2024Q3 bior Related Party Senior Secured Convertible Notes
RelatedPartySeniorSecuredConvertibleNotes
19721000
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4527000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14591000
CY2023Q4 bior Related Party Senior Secured Convertible Notes
RelatedPartySeniorSecuredConvertibleNotes
21155000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
9966000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000000
bior Class Of Warrant Or Right Period For Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable
after September 18, 2023 until September 18, 2026
CY2023Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
53200000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35100000
CY2023 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
25500000
CY2023 bior Troubled Debt Restructuring Debtor Future Interest Payments Capitalized
TroubledDebtRestructuringDebtorFutureInterestPaymentsCapitalized
11700000
bior Forbearance Agreement Maturity Date
ForbearanceAgreementMaturityDate
2024-10-31
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
235000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
311000
us-gaap Operating Lease Cost
OperatingLeaseCost
706000
us-gaap Operating Lease Cost
OperatingLeaseCost
1104000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
259000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
590000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
264000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18000
CY2024Q3 bior Lessee Operating Lease Liability Payments Due Year After
LesseeOperatingLeaseLiabilityPaymentsDueYearAfter
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1131000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
77000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1054000
CY2020Q3 bior Number Of States Participating In Settlement
NumberOfStatesParticipatingInSettlement
45
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2800000
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
1700000
CY2024Q4 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
300000
CY2024Q3 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2300000
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1000000
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On January 3, 2023, the Company effected the 2023 Reverse Stock Split of the Company's common stock.
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
53
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
301886
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
50.5
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7300000
CY2023Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
CY2023Q2 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
1000000
CY2023Q2 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
700000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
100000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
427807
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
19.3
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
18.7
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
9900000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6700000
CY2023Q4 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
6700000
CY2024Q1 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
1500000
CY2024Q2 bior Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
5500000
CY2024Q1 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
700000
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7141572
CY2022Q4 bior Number Of Vote Per Preferred Stock Held
NumberOfVotePerPreferredStockHeld
3000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
76301
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
362.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10880
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.52
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3795
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
248.08
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
83386
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
321.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
83386
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
321.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
44243
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
480.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.047
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.044
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.928
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.968
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.985
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.5
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.76
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1281000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10531000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4393000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14929000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15387216
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3378248
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 bior Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 bior Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127060-index-headers.html Edgar Link pending
0000950170-24-127060-index.html Edgar Link pending
0000950170-24-127060.txt Edgar Link pending
0000950170-24-127060-xbrl.zip Edgar Link pending
bior-20240930.htm Edgar Link pending
bior-20240930.xsd Edgar Link pending
bior-ex31_1.htm Edgar Link pending
bior-ex31_2.htm Edgar Link pending
bior-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
bior-20240930_htm.xml Edgar Link completed
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable